Does the media favor IRON or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Disc Medicine. MarketBeat recorded 25 mentions for Arrowhead Pharmaceuticals and 17 mentions for Disc Medicine. Arrowhead Pharmaceuticals' average media sentiment score of 0.72 beat Disc Medicine's score of 0.64 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 8 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better earnings and valuation, IRON or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is IRON or SMMT more profitable?

Disc Medicine's return on equity of -37.17% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to IRON or SMMT?

In the previous week, Disc Medicine had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 17 mentions for Disc Medicine and 13 mentions for Summit Therapeutics. Disc Medicine's average media sentiment score of 0.64 beat Summit Therapeutics' score of 0.61 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRON or KRYS?

In the previous week, Disc Medicine had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 17 mentions for Disc Medicine and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.69 beat Disc Medicine's score of 0.64 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer IRON or IONS?

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Disc Medicine. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 17 mentions for Disc Medicine. Ionis Pharmaceuticals' average media sentiment score of 1.20 beat Disc Medicine's score of 0.64 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, IRON or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is IRON or ABVX more profitable?

Disc Medicine's return on equity of -37.17% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Abivax N/A -99.02% -70.26%

Does the media prefer IRON or ABVX?

In the previous week, Disc Medicine had 16 more articles in the media than Abivax. MarketBeat recorded 17 mentions for Disc Medicine and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Disc Medicine's score of 0.64 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Disc Medicine (IRON) Competitors

$79.85 -0.20 (-0.24%)

As of 12:58 PM Eastern

Compare

IRON vs. ARWR, SMMT, KRYS, IONS, and ABVX

Should you buy Disc Medicine stock or one of its competitors? Disc Medicine's main competitors and comparable companies include Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), Ionis Pharmaceuticals (IONS), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Disc Medicine (NASDAQ:IRON) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Disc Medicine has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Disc Medicine's return on equity of -37.17% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Disc Medicine has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Disc Medicine. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Arrowhead Pharmaceuticals	$669.50M	17.94	-$1.63M	-$2.25	N/A

Disc Medicine currently has a consensus price target of $107.70, suggesting a potential upside of 35.51%. Arrowhead Pharmaceuticals has a consensus price target of $98.42, suggesting a potential upside of 15.44%. Given Disc Medicine's stronger consensus rating and higher probable upside, research analysts plainly believe Disc Medicine is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Disc Medicine. MarketBeat recorded 25 mentions for Arrowhead Pharmaceuticals and 17 mentions for Disc Medicine. Arrowhead Pharmaceuticals' average media sentiment score of 0.72 beat Disc Medicine's score of 0.64 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Disc Medicine beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Summit Therapeutics?

Disc Medicine (NASDAQ:IRON) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Disc Medicine has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, Disc Medicine had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 17 mentions for Disc Medicine and 13 mentions for Summit Therapeutics. Disc Medicine's average media sentiment score of 0.64 beat Summit Therapeutics' score of 0.61 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Disc Medicine's return on equity of -37.17% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Summit Therapeutics	N/A	-168.94%	-141.92%

Disc Medicine currently has a consensus target price of $107.70, suggesting a potential upside of 35.51%. Summit Therapeutics has a consensus target price of $24.07, suggesting a potential upside of 44.88%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summary

Disc Medicine beats Summit Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Krystal Biotech?

Disc Medicine (NASDAQ:IRON) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Krystal Biotech has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Krystal Biotech	$389.13M	28.18	$204.83M	$7.98	46.43

Disc Medicine has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, Disc Medicine had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 17 mentions for Disc Medicine and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.69 beat Disc Medicine's score of 0.64 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Disc Medicine currently has a consensus price target of $107.70, suggesting a potential upside of 35.51%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential downside of 1.38%. Given Disc Medicine's higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Disc Medicine's net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats Disc Medicine on 12 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Ionis Pharmaceuticals?

Disc Medicine (NASDAQ:IRON) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Disc Medicine has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Ionis Pharmaceuticals	$874.09M	11.13	-$381.39M	-$3.46	N/A

Disc Medicine has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Disc Medicine's return on equity of -37.17% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Disc Medicine. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 17 mentions for Disc Medicine. Ionis Pharmaceuticals' average media sentiment score of 1.20 beat Disc Medicine's score of 0.64 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Disc Medicine presently has a consensus price target of $107.70, indicating a potential upside of 35.51%. Ionis Pharmaceuticals has a consensus price target of $94.15, indicating a potential upside of 60.76%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Ionis Pharmaceuticals beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Abivax?

Disc Medicine (NASDAQ:IRON) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Disc Medicine's return on equity of -37.17% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Abivax	N/A	-99.02%	-70.26%

Disc Medicine currently has a consensus price target of $107.70, suggesting a potential upside of 35.51%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 35.88%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Disc Medicine has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Abivax has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Disc Medicine had 16 more articles in the media than Abivax. MarketBeat recorded 17 mentions for Disc Medicine and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Disc Medicine's score of 0.64 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Disc Medicine beats Abivax on 8 of the 13 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.05B	$4.02B	$7.26B	$12.90B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-12.08	12.34	273.76	25.42
Price / Sales	N/A	1,373.91	679.75	124.45
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	4.74	16.39	12.91	6.15
Net Income	-$212.18M	-$22.72M	$3.48B	$349.24M
7 Day Performance	-3.73%	-1.39%	-0.18%	-1.39%
1 Month Performance	4.15%	11.08%	6.63%	2.55%
1 Year Performance	29.04%	53.50%	25.25%	15.80%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.4963 of 5 stars	$79.85 -0.2%	$107.70 +34.9%	+30.4%	$3.06B	N/A	N/A	30	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2333 of 5 stars	$82.74 +0.4%	$98.42 +18.9%	+232.4%	$11.65B	$829.45M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	3.502 of 5 stars	$14.16 +4.0%	$24.07 +70.0%	-38.8%	$11.30B	N/A	N/A	110	Analyst Forecast Gap Up
KRYS Krystal Biotech	2.6396 of 5 stars	$363.84 +1.2%	$365.40 +0.4%	+147.8%	$10.77B	$389.13M	45.59	210	Positive News
IONS Ionis Pharmaceuticals	3.7465 of 5 stars	$59.88 -0.8%	$94.15 +57.2%	+6.7%	$9.95B	$944M	N/A	1,402	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. ARWR, SMMT, KRYS, IONS, and ABVX

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Summary

How does Disc Medicine compare to Summit Therapeutics?

Summary

How does Disc Medicine compare to Krystal Biotech?

Summary

How does Disc Medicine compare to Ionis Pharmaceuticals?

Summary

How does Disc Medicine compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. ARWR, SMMT, KRYS, IONS, and ABVX

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Is IRON or ARWR more profitable?

Which has more risk & volatility, IRON or ARWR?

Which has better earnings and valuation, IRON or ARWR?

Do analysts rate IRON or ARWR?

Do insiders & institutionals have more ownership in IRON or ARWR?

Does the media favor IRON or ARWR?

Summary

How does Disc Medicine compare to Summit Therapeutics?

Which has more risk and volatility, IRON or SMMT?

Which has better earnings and valuation, IRON or SMMT?

Does the media refer more to IRON or SMMT?

Do institutionals & insiders hold more shares of IRON or SMMT?

Is IRON or SMMT more profitable?

Do analysts recommend IRON or SMMT?

Summary

How does Disc Medicine compare to Krystal Biotech?

Which has better earnings and valuation, IRON or KRYS?

Which has more volatility and risk, IRON or KRYS?

Does the media prefer IRON or KRYS?

Do analysts prefer IRON or KRYS?

Do institutionals and insiders hold more shares of IRON or KRYS?

Is IRON or KRYS more profitable?

Summary

How does Disc Medicine compare to Ionis Pharmaceuticals?

Which has preferable earnings and valuation, IRON or IONS?

Is IRON or IONS more profitable?

Does the media prefer IRON or IONS?

Do institutionals and insiders believe in IRON or IONS?

Which has more risk & volatility, IRON or IONS?

Do analysts prefer IRON or IONS?

Summary

How does Disc Medicine compare to Abivax?

Which has higher valuation & earnings, IRON or ABVX?

Do institutionals & insiders have more ownership in IRON or ABVX?

Is IRON or ABVX more profitable?

Do analysts recommend IRON or ABVX?

Which has more volatility and risk, IRON or ABVX?

Does the media prefer IRON or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools